- Home
- ES vs ROIV Comparison
ES vs ROIV Comparison
Compare ES & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ES | ROIV |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 20.7B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ES | ROIV |
|---|---|---|
| Price | $68.20 | $29.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $71.00 | $28.94 |
| AVG Volume (30 Days) | 1.8M | ★ 4.4M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 100.88 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $13,547,244,000.00 | $29,053,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.77 | $744.61 |
| P/E Ratio | $42.68 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $61.53 | $10.58 |
| 52 Week High | $76.41 | $30.33 |
Technical Indicators
Market Signals| Indicator | ES | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 58.42 |
| Support Level | $65.62 | $27.00 |
| Resistance Level | $68.84 | $30.26 |
| Average True Range (ATR) | 1.37 | 0.86 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 34.48 | 83.58 |
Price Performance
Historical ComparisonAbout ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.